Marta Trapero-Bertran

Marta Trapero-Bertran

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
JLJ Lord
J Lord
SWS Willis
S Willis
JEJ Eatock
J Eatock
PTP Tappenden
P Tappenden
MTMarta Trapero-Bertran
Marta Trapero-Bertran
FRF Ruiz
F Ruiz
Background National Institute for Health and Care Excellence (NICE) clinical guidelines (CGs) make recommendations across large, complex care pathways for broad groups of patients. They rely on cost-effectiveness evidence from the literature and from new analyses for selected high-priority topics. An alternative approach would be to build a model of the full care pathway and to use this as a platform to evaluate the cost-effectiveness of multiple topics across the guideline recommendations. Objectives In this project we aimed to test the feasibility of building full guideline models for NICE guidelines and to assess if, and how, such models can be used as a basis for cost-effectiveness analysis (CEA). Data sources A ‘best evidence’ approach was used to inform the model parameters. Data were drawn from the guideline documentation, advice from clinical experts and rapid literature reviews on selected topics. Where possible we relied on good-quality, recent UK systematic reviews and meta-analyses. Review methods Two published NICE guidelines were used as case studies: prostate cancer and atrial fibrillation (AF). Discrete event simulation (DES) was used to model the recommended care pathways and to estimate consequent costs and outcomes. For each guideline, researchers not involved in model development collated a shortlist of topics suggested for updating. The modelling teams then attempted to evaluate options related to these topics. Cost-effectiveness results were compared with opinions about the importance of the topics elicited in a survey of stakeholders. Results The modelling teams developed simulations of the guideline pathways and disease processes. Development took longer and required more analytical time than anticipated. Estimates of cost-effectiveness were produced for six of the nine prostate cancer topics considered, and for five of eight AF topics. The other topics were not evaluated owing to lack of data or time constraints. The modelled results suggested ‘economic priorities’ for an update that differed from priorities expressed in the stakeholder survey. Limitations We did not conduct systematic reviews to inform the model parameters, and so the results might not reflect all current evidence. Data limitations and time constraints restricted the number of analyses that we could conduct. We were also unable to obtain feedback from guideline stakeholders about the usefulness of the models within project time scales. Conclusions Discrete event simulation can be used to model full guideline pathways for CEA, although this requires a substantial investment of clinical and analytic time and expertise. For some topics lack of data may limit the potential for modelling. There are also uncertainties over the accessibility and adaptability of full guideline models. However, full guideline modelling offers the potential to strengthen and extend the analytical basis of NICE’s CGs. Further work is needed to extend the analysis of our case study models to estimate population-level budget and health impacts. The practical usefulness of our models to guideline developers and users should also be investigated, as should the feasibility and usefulness of whole guideline modelling alongside development of a new CG. Funding This project was funded by the Medical Research Council and the National Institute for Health Research through the Methodology Research Programme [grant number G0901504] and will be published in full in Health Technology Assessment; Vol. 17, No. 58. See the NIHR Journals Library website for further project information.

18 July 2018 in BMC Public Health
Verified
Journal Article
Open access
PDF file
TMToni Mora
Toni Mora
MTMarta Trapero-Bertran
Marta Trapero-Bertran
In order to enhance childhood vaccination uptake and the health consequences for the whole society, there is a need to study predictors that might help in understanding parents’ behaviour in relation to childhood vaccination schemes. The aim of this paper is to assess whether parental education has an influence on their children’s public health-care use in terms of visits for vaccinations, and thus evaluate whether more educated parents use public health resources more frequently in childhood immunization schedules. The setting was the region of Catalonia in the north-east of Spain. Three different databases, containing information about 11,415 individuals corresponding to 79,905 observations, were merged and linked: 1) observational and longitudinal administrative data for adults and children in Catalonia; 2) a database containing information on the vaccination of children in relation to the public health programme called the “Healthy Child Programme”; and 3) the governmental vaccination registration. The presence of an education gradient was explored using a logistic regression. Children’s health-care use was modelled using a logistic procedure. The greater the mothers’ educational attainment level, the higher the probability of being vaccinated in this immunization programme. The presence of an age profile for vaccinations showed that less educated parents visit their GPs more frequently for immunizations when their children are below the age of six, but that pattern is completely the opposite after that age. Hence, for children aged between six and 16, more educated parents are more likely to ensure their children are immunized. Likewise, systematic vaccinations are more likely for those parents with a lower educational attainment level. This paper evidenced the presence of an education gradient for specific preventive care through the public health system and visits to the GP without any particular disease or advice for specific vaccinations.

4 October 2022 in Environmental Research
Verified
Journal Article
Closed access
LFLaia Font-Ribera
Laia Font-Ribera
MRMarc Rico
Marc Rico
MMMarc Marí-Dell’OLmo
Marc Marí-Dell’OLmo
LOLaura Oliveras
Laura Oliveras
MTMarta Trapero-Bertran
Marta Trapero-Bertran
AGAnna Gómez-Gutiérrez
Anna Gómez-Gutiérrez

1 January 2019 in Resuscitation
Verified
Journal Article
Closed access
Jordi Castillo GarciaJordi Castillo Garcia
Jordi Castillo Garcia
CGCarmen Gomar
Carmen Gomar
EREncarna Rodriguez-Higueras
Encarna Rodriguez-Higueras
MTMarta Trapero-Bertran
Marta Trapero-Bertran
AFAlberto Gallart Gallart Fernández-Puebla
Alberto Gallart Gallart Fernández-Puebla

1 December 2019 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
AVAna-Magdalena Vargas-Martinez
Ana-Magdalena Vargas-Martinez
MTMarta Trapero-Bertran
Marta Trapero-Bertran
Marta Lima-SerranoMarta Lima-Serrano
Marta Lima-Serrano
NANana Anokye
Nana Anokye
SPSubhash Pokhrel
Subhash Pokhrel
TMToni Mora
Toni Mora

29 May 2018 in BioDrugs
Verified
Journal Article
Open access
PDF file
NZNéboa Zozaya
Néboa Zozaya
LMLucía Martínez-Galdeano
Lucía Martínez-Galdeano
BABleric Alcalá
Bleric Alcalá
JAJose Carlos Armario-Hita
Jose Carlos Armario-Hita
CCConcepción Carmona
Concepción Carmona
ÁHÁlvaro Hidalgo-Vega
Álvaro Hidalgo-Vega
Multi-criteria decision analysis (MCDA) is a tool that systematically considers multiple factors relevant to health decision-making. The aim of this study was to use an MCDA to assess the value of dupilumab for severe atopic dermatitis compared with secukinumab for moderate to severe plaque psoriasis in Spain.